Skip to main content

Advertisement

SpringerLink
Log in

Trastuzumab in metastatic breast cancer after complete remission: How long is enough?

  • Letter to the Editor
  • Published:
Medical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, et al. Pertuzumab, Trastuzumab and Docetaxel in HER2 positive metastatic breast cancer. NEJM. 2015;372:724–34.

    Article  CAS  PubMed  Google Scholar 

  2. Arciénega II, Imesch P, Fink D, Dedes KJ. Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: A case report and review of the literature. Target Oncol. 2015;10(2):297–301.

    Article  Google Scholar 

  3. Yan M, Lv HM, Zhang MW, Cui SD. Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: Two case reports and literature review. Chin J Cancer Res. 2014;26(4):486–92.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Montemurro F, Prat A, Rossi V, Valabrega G, Sperinde J, Peraldo-Neia C, et al. Potential biomarkers of long term benefit from single agent trastuzumab or lapatinib in HER 2 positive metastatic breast cancer. Mol Oncol. 2014;8(1):20–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Medical Oncology Department, Baskent University, 5th Street Bahcelievler, Ankara, Turkey

    Arzu Oguz, Samed Rahatli & Ozden Altundag

  2. Hacettepe University, Ankara, Turkey

    Kadri Altundag

Authors
  1. Arzu Oguz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samed Rahatli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ozden Altundag
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kadri Altundag
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arzu Oguz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oguz, A., Rahatli, S., Altundag, O. et al. Trastuzumab in metastatic breast cancer after complete remission: How long is enough?. Med Oncol 32, 211 (2015). https://doi.org/10.1007/s12032-015-0648-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-015-0648-1

Keywords

Search

Navigation